Targeting Pro-Inflammatory Interleukin-1 Beta Signaling to Modulate Neuroinflammatory Processes Associated with Cognitive Decline in Dementia with Lewy Bodies
Highlights What are the main findings? The oral p38α kinase inhibitor neflamapimod potently (EC50 ~6 nM) inhibits IL-1β-induced IL-6 and IL-8 production from human peripheral blood mononuclear cells. In clinical studies, neflamapimod reduces CSF levels of IL-6 and IL-8 in patients with early Alzheimer’s disease, and in...